● Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Condition: Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) · Sponsor: Novartis Pharmaceuticals

PhasePhase 3

Planned participants240

Who can joinAll sexes, 12 Years to 100 Years

Healthy volunteersNo

About this study

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (65)

Mayo Clinic Arizona	Scottsdale, Arizona, United States	Recruiting
Highlands Oncology Group	Fayetteville, Arkansas, United States	Recruiting
Rocky Mountain Cancer Centers	Denver, Colorado, United States	Recruiting
Hartford Hospital	Hartford, Connecticut, United States	Recruiting
Yale New Haven Hospital	New Haven, Connecticut, United States	Recruiting
Mayo Clinic Jacksonville	Jacksonville, Florida, United States	Recruiting
Winship Cancer Institute	Atlanta, Georgia, United States	Recruiting
St Elizabeth Healthcare	Edgewood, Kentucky, United States	Recruiting
LSU Medical Center	New Orleans, Louisiana, United States	Recruiting
Henry Ford Hospital	Detroit, Michigan, United States	Recruiting
Mount Sinai Medical Center	New York, New York, United States	Recruiting
Piedmont Healthcare	Winston-Salem, North Carolina, United States	Recruiting

+ 53 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06784752